These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 8965130)

  • 1. Drug-induced hyperthermia in a patient with persistent vegetative state. Case report and review of the literature.
    Berlot G; Tomasini A; Cociancich N; Viviani M; Gullo A
    J Neurosurg Sci; 1995 Sep; 39(3):199-202. PubMed ID: 8965130
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Bromocriptine in Parkinsonian syndromes. Results obtained in a group of patients treated for 8 months].
    Quattrini A; Paggi A; Del Pesce M; Di Bella P
    Riv Patol Nerv Ment; 1978; 99(3):150-63. PubMed ID: 752907
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparison of bromocriptine (Parlodel) and levodopa-carbidopa (Sinemet) for treatment of "de novo" Parkinson's disease patients.
    Libman I; Gawel MJ; Riopelle RJ; Bouchard S
    Can J Neurol Sci; 1987 Nov; 14(4):576-80. PubMed ID: 3319120
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuroleptic malignant syndrome without neuroleptics.
    Ong KC; Chew EL; Ong YY
    Singapore Med J; 2001 Feb; 42(2):85-8. PubMed ID: 11358199
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Effect on morphine hyperthermia of dopaminergic agents].
    Iakimova K; Koleva E; Bantutova I; Ovcharova R
    Eksp Med Morfol; 1985; 24(4):21-7. PubMed ID: 3833520
    [No Abstract]   [Full Text] [Related]  

  • 6. Hyperthermia associated with drug intoxication.
    Rosenberg J; Pentel P; Pond S; Benowitz N; Olson K
    Crit Care Med; 1986 Nov; 14(11):964-9. PubMed ID: 3769509
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypersexuality--a complication of dopaminergic therapy in Parkinson's disease.
    Vogel HP; Schiffter R
    Pharmacopsychiatria; 1983 Jul; 16(4):107-10. PubMed ID: 6685318
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Pathological gambling behavior in a patient with Parkinson's disease treated with levodopa and bromocriptine].
    Montastruc JL; Schmitt L; Bagheri H
    Rev Neurol (Paris); 2003 Apr; 159(4):441-3. PubMed ID: 12773874
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [L-dopa and bromocriptine in Parkinson disease. Early combination therapy has better effect].
    Olsson JE; Duchek M; Ekberg R; Fehling C; Johansson F; Johnels B; Lindvall B; Nordin G; Sidén A; Steg G
    Lakartidningen; 1993 Apr; 90(16):1545-8. PubMed ID: 8483351
    [No Abstract]   [Full Text] [Related]  

  • 10. Effectively managing intractable central hyperthermia in a stroke patient by bromocriptine: a case report.
    Yu KW; Huang YH; Lin CL; Hong CZ; Chou LW
    Neuropsychiatr Dis Treat; 2013; 9():605-8. PubMed ID: 23662059
    [TBL] [Abstract][Full Text] [Related]  

  • 11. De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-dopa in the MPTP-treated marmoset.
    Pearce RK; Banerji T; Jenner P; Marsden CD
    Mov Disord; 1998 Mar; 13(2):234-41. PubMed ID: 9539335
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Attenuation of MDMA-induced hyperthermia by ethanol in rats depends on ambient temperature.
    Cassel JC; Ben Hamida S; Jones BC
    Eur J Pharmacol; 2007 Oct; 571(2-3):152-5. PubMed ID: 17617399
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A six-month multicentre, double-blind, bromocriptine-controlled study of the safety and efficacy of ropinirole in the treatment of patients with Parkinson's disease not optimally controlled by L-dopa.
    Brunt ER; Brooks DJ; Korczyn AD; Montastruc JL; Stocchi F;
    J Neural Transm (Vienna); 2002 Apr; 109(4):489-502. PubMed ID: 11956968
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuroleptic malignant syndrome in a patient with Parkinson's disease: a case study.
    Ward C
    J Neurosci Nurs; 2005 Jun; 37(3):160-2. PubMed ID: 16001822
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and tolerability of tolcapone compared with bromocriptine in levodopa-treated parkinsonian patients. Tolcapone Study Group.
    Mov Disord; 1999 Jan; 14(1):38-44. PubMed ID: 9918342
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationship between methamphetamine-induced behavioral activation and hyperthermia.
    Phelps G; Speaker HA; Sabol KE
    Brain Res; 2010 Oct; 1357():41-52. PubMed ID: 20709036
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Functional hyperthermia due to central dopaminergic impairment.
    Di Rosa AE; Morgante L; Coraci MA; Crisafulli A; Cacciola G; Di Stefano G; Meduri M; Di Perri R
    Funct Neurol; 1988; 3(2):211-5. PubMed ID: 2900182
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Bromocriptine in the treatment of patients with parkinsonism and dyskinesias induced by levodopa].
    Haas JA; Lakke JP
    Ned Tijdschr Geneeskd; 1982 Apr; 126(16):701-5. PubMed ID: 7088202
    [No Abstract]   [Full Text] [Related]  

  • 19. An uncommon adverse effect of levodopa withdrawal in a patient taking antipsychotic medication: neuroleptic malignant-like syndrome.
    Man SP
    Hong Kong Med J; 2011 Feb; 17(1):74-6. PubMed ID: 21282831
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Malignant hyperthermia and generalized muscle rigidity during general anesthesia].
    Brückner JB; Gethmann JW; Bartels M; Eberlein HJ
    Z Prakt Anasth; 1970 Oct; 5(5):305-10. PubMed ID: 4256240
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.